Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Half-Year Revenues of 4 Japanese Majors Beat Projections on Buoyant Global Products
November 6, 2015
- Ono Now Has Oncology Sales Force of 180, Eyes Lung Cancer Indication for Opdivo
November 6, 2015
- Nichi-Iko Eyes Generic Production Capacity of 21 Billion Tablets by 2021
November 5, 2015
- AbbVie Files Humira for Non-Infectious Uveitis
November 5, 2015
- Astellas to Transfer Kiyosu Plant Business to MicroBiopharm Japan
November 4, 2015
- Mochida Seeks Japan Approval of Ulcerative Colitis Drug
November 4, 2015
- AbbVie Files Parkinson’s Treatment in Japan
November 4, 2015
- Edoxaban Flounders in US but No Change to FY2017 Biz Targets: Daiichi Sankyo CEO
November 4, 2015
- Mitsubishi Tanabe to Cut Back on Jobs in Japan
November 4, 2015
- Mitsubishi Tanabe Sales Tick Up as Royalty Income Increases
November 4, 2015
- Daiichi Sankyo Recalls Measles, Rubella Vaccines
November 4, 2015
- Takeda Drops Development of TAK-264, TAK-272
November 2, 2015
- Sakigake Designation System Very Useful: Astellas President
November 2, 2015
- Eisai Squeezes Out Sales Rise on Growing Global Brands
November 2, 2015
- Daiichi Sankyo’s Half-Year Revenue Up 11% Due to Growth in Sales in Japan and US; Operating Profit Up 61%
November 2, 2015
- Xtandi Makes Strong Contribution to Astellas’s Half-Year Sales and Profits
November 2, 2015
- Entyvio’s Sales Jump Underpins Takeda’s Half-Year Revenue
November 2, 2015
- Shionogi Delivers Record Profits in April-September on Brisk HIV Franchise
October 30, 2015
- Sakigake Designated Anticancer Agent ASP2215 Enters Multinational PIII Study: Astellas
October 30, 2015
- Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
October 29, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…